Cardiological Findings in Children and Adolescents Before and After Guanfacine Treatment for Attention Deficit and Hyperactivity Disorder

被引:0
|
作者
Yukcu, Bekir [1 ]
Onal, Bedia Sultan [2 ]
Osmanli, Cansu Cobanoglu [2 ]
Tonkaz, Gulsum Yitik [2 ]
Sahin, Berkan [2 ]
机构
[1] Giresun Matern & Children Training & Res Hosp, Dept Pediat Cardiol, TR-28200 Giresun, Turkiye
[2] Giresun Univ, Dept Child & Adolescent Psychiat, Fac Med, TR-28200 Giresun, Turkiye
来源
CHILDREN-BASEL | 2025年 / 12卷 / 03期
关键词
ADHD; guanfacine; cardiovascular safety; electrocardiography; EXTENDED-RELEASE GUANFACINE; DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; ALPHA-2; AGONISTS; LONG-TERM; TP-E/QT; ADHD; STIMULANT; PSYCHOSTIMULANTS; METAANALYSIS;
D O I
10.3390/children12030302
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: This study evaluates the short-term cardiovascular effects of guanfacine treatment in children and adolescents with attention deficit/hyperactivity disorder (ADHD). The treatment's impact on novel electrocardiographic parameters was also investigated. Methods: In a retrospective study conducted between January 2023 and June 2024, 37 patients aged 6-18 years with ADHD underwent baseline and follow-up cardiac evaluations including electrocardiography (ECG) and blood pressure measurements. Novel ECG markers (QRS-T angle, QT dispersion, QTc dispersion, Tp-e interval, Tp-e dispersion, Tp-e/QT ratio, and Tp-e/QTc ratio) were analyzed alongside standard parameters such as heart rate, QT, and corrected QT (QTc) intervals. Guanfacine was initiated at 1 mg and titrated weekly until an optimal clinical response was achieved. Results: Guanfacine treatment led to a significant reduction in heart rate (-12.3 bpm; p < 0.001) and P wave axis (-12.3 degrees; p = 0.038) and an increase in QT interval (+16.8 ms; p = 0.014). However, no significant changes were observed in blood pressure, QTc duration, or the novel ECG parameters. Importantly, the absence of any changes in these advanced markers supports the cardiovascular safety of guanfacine. Two patients experienced side effects (bradycardia and hypotension), leading to treatment discontinuation. ANCOVA analysis indicated that the duration between ECG evaluations significantly influenced the QT interval changes, emphasizing the importance of timing when monitoring cardiovascular effects. Conclusions: Guanfacine demonstrated minor, statistically significant effects on the selected cardiac parameters without clinically meaningful changes to or adverse impacts on the novel ECG markers investigated. As extended-release guanfacine has only been available in T & uuml;rkiye for the management of ADHD for approximately two years, studies evaluating its clinical efficacy and side effects are critical for clinicians working in this field.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Treatment of attention deficit hyperactivity disorder in children and adolescents - Safety considerations
    Wolraich, Mark L.
    McGuinn, Laura
    Doffing, Melissa
    DRUG SAFETY, 2007, 30 (01) : 17 - 26
  • [22] Transcranial micropolarization in treatment of attention deficit hyperactivity disorder in children and adolescents
    Kropotov, YD
    Chutko, LS
    Yakovenko, VA
    Grin-Yatsenko, VA
    ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2002, 102 (05): : 26 - 28
  • [23] Practitioner characteristics and the treatment of children and adolescents with attention deficit hyperactivity disorder
    Mitchell, Philip B.
    Levy, Florence
    Hadzi-Pavlovic, Dusan
    Concannon, Patrick E.
    Hutchins, Paul
    Mulcahy, Desmond L.
    Clarke, Simon D.
    Salmelainen, Pia A.
    Warner, Alexandra
    Hughes, Clifford F.
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2012, 48 (06) : 483 - 489
  • [24] Efficacy of atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder
    Dunn, D
    Allen, A
    Thomason, C
    Zhang, S
    Michelson, D
    Kelsey, D
    ANNALS OF NEUROLOGY, 2003, 54 : S143 - S143
  • [25] Clinical guidelines for the treatment of attention deficit hyperactivity disorder in children and adolescents
    Ulloa, RE
    Arroyo, E
    Avila, JM
    Cárdenas, JA
    Cruz, E
    Gómez, D
    Higuera, F
    Rivera, F
    Santos, G
    Velásquez, V
    de la Peña, F
    SALUD MENTAL, 2005, 28 (05) : 1 - 10
  • [26] Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder
    Najib, Jadwiga
    ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS, 2012, 3 : 51 - 66
  • [27] Diagnosis and treatment of children and adolescents with attention-deficit/hyperactivity disorder
    Brown, MB
    JOURNAL OF COUNSELING AND DEVELOPMENT, 2000, 78 (02): : 195 - 203
  • [28] Treatment experiences of children and adolescents with attention-deficit/hyperactivity disorder
    Leggett, Catherine
    Hotham, Elizabeth
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2011, 47 (08) : 512 - 517
  • [29] Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder
    Findling, Robert L.
    Greenhill, Laurence L.
    McNamara, Nora K.
    Demeter, Christine A.
    Kotler, Lisa A.
    O'Riordan, Mary Ann
    Myers, Carolyn
    Reed, Michael D.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2007, 17 (04) : 433 - 445
  • [30] PHARMACOTHERAPEUTIC TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS
    Regnart, J.
    McCartney, J.
    Truter, I
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 148 - 148